Adam Dubow - 15 Feb 2025 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
GENERAL COUNSEL
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
15 Feb 2025
Net transactions value
-$55,580
Form type
4
Filing time
21 Feb 2025, 18:08:31 UTC
Previous filing
31 Jan 2025
Next filing
19 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise +2,962 +9.2% 35,124 15 Feb 2025 Direct F1
transaction DAWN Common Stock Options Exercise +1,750 +5% 36,874 15 Feb 2025 Direct F1
transaction DAWN Common Stock Options Exercise +3,687 +10% 40,561 15 Feb 2025 Direct F1
transaction DAWN Common Stock Options Exercise +3,687 +9.1% 44,248 15 Feb 2025 Direct F1
transaction DAWN Common Stock Sale $55,580 -4,646 -10% $11.96 39,602 18 Feb 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -2,962 -12% $0.000000 20,740 15 Feb 2025 Common Stock 2,962 Direct F1, F4, F5
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -1,750 -12% $0.000000 12,250 15 Feb 2025 Common Stock 1,750 Direct F1, F5, F6
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -3,687 -8.3% $0.000000 40,565 15 Feb 2025 Common Stock 3,687 Direct F1, F5, F6
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -3,687 -6.2% $0.000000 55,313 15 Feb 2025 Common Stock 3,687 Direct F1, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
F3 The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.86 to $12.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade.
F4 The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments thereafter on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F5 RSUs do not expire; they either vest or are canceled prior to the vesting date.
F6 The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.